Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analyses of IBCGS TEXT and SOFT trials; - Pagani, O; Regan, M M; Walley, B (2014)
Abstract LBA1, ASCO